| Medical and Health Sciences | 2021-2025 | 678 | BY 1 | 99.85 |
| Dermatology | Lifetime | 120 | BY 1 | 99.19 |
| Biotechnology | Lifetime | 642 | BY 1 | 87.80 |
| Dermatology | 2021-2025 | 24 | BY 1 | 99.65 |
| Immunology | 2021-2025 | 160 | BY 1 | 96.61 |
| Oncology | 2021-2025 | 291 | BY 1 | 97.37 |
| Epidemiology | 2021-2025 | 439 | BY 1 | 96.19 |
| Pathology and Forensic Medicine | 2021-2025 | 377 | BY 1 | 85.97 |
| Cutaneous lymphoproliferative disorders research | Lifetime | 65 | BY 1 | 99.08 |
| Cutaneous Melanoma Detection and Management | Lifetime | 192 | BY 1 | 98.50 |
| Lymphoma Diagnosis and Treatment | Lifetime | 732 | BY 1 | 98.27 |
| Fungal Infections and Studies | Lifetime | 410 | BY 1 | 97.28 |
| T-cell and Retrovirus Studies | Lifetime | 320 | BY 1 | 96.90 |
| Autoimmune Bullous Skin Diseases | Lifetime | 566 | BY 2 | 96.24 |
| Melanoma and MAPK Pathways | Lifetime | 373 | BY 1 | 96.27 |
| Nonmelanoma Skin Cancer Studies | Lifetime | 427 | BY 1 | 96.10 |
| melanin and skin pigmentation | Lifetime | 476 | BY 1 | 95.51 |
| Psoriasis: Treatment and Pathogenesis | Lifetime | 559 | BY 1 | 95.88 |
| Nail Diseases and Treatments | Lifetime | 924 | BY 1 | 93.82 |
| Autoimmune and Inflammatory Disorders | Lifetime | 672 | BY 1 | 91.17 |
| Hidradenitis Suppurativa and Treatments | Lifetime | 285 | BY 1 | 86.28 |
| Dermatological and COVID-19 studies | Lifetime | 586 | BY 1 | 80.09 |
| Cutaneous lymphoproliferative disorders research | 2021-2025 | 2 | BY 1 | 99.66 |
| Cutaneous Melanoma Detection and Management | 2021-2025 | 50 | BY 1 | 98.26 |
| Nail Diseases and Treatments | 2021-2025 | 39 | BY 1 | 96.93 |
| Melanoma and MAPK Pathways | 2021-2025 | 38 | BY 1 | 97.87 |
| Dermatology and Skin Diseases | 2021-2025 | 128 | BY 2 | 97.94 |
| Nonmelanoma Skin Cancer Studies | 2021-2025 | 71 | BY 1 | 95.98 |
| Lymphoma Diagnosis and Treatment | 2021-2025 | 366 | BY 1 | 96.66 |
| Psoriasis: Treatment and Pathogenesis | 2021-2025 | 131 | BY 2 | 97.25 |
| Cancer Immunotherapy and Biomarkers | 2021-2025 | 948 | BY 1 | 96.35 |
| CAR-T cell therapy research | 2021-2025 | 763 | BY 2 | 95.59 |
| Asthma and respiratory diseases | 2021-2025 | 469 | BY 3 | 95.66 |
| Dermatological and COVID-19 studies | 2021-2025 | 47 | BY 1 | 88.68 |
| Fungal Infections and Studies | 2021-2025 | 233 | BY 1 | 93.37 |
| Autoimmune Bullous Skin Diseases | 2021-2025 | 226 | BY 1 | 92.74 |
| Hidradenitis Suppurativa and Treatments | 2021-2025 | 95 | BY 1 | 88.95 |
| T-cell and Retrovirus Studies | 2021-2025 | 175 | BY 1 | 86.40 |
| Colorectal and Anal Carcinomas | 2021-2025 | 693 | BY 1 | 85.70 |
| melanin and skin pigmentation | 2021-2025 | 350 | BY 1 | 81.94 |
| Skin Protection and Aging | 2021-2025 | 530 | BY 1 | 81.56 |
| Hair Growth and Disorders | 2021-2025 | 340 | BY 2 | 78.13 |
| Cancer and Skin Lesions | 2021-2025 | 455 | BY 1 | 75.33 |
| Urticaria and Related Conditions | 2021-2025 | 976 | BY 3 | 74.12 |
| Autoimmune and Inflammatory Disorders | 2021-2025 | 562 | BY 2 | 68.76 |
| Toxin Mechanisms and Immunotoxins | 2021-2025 | 744 | BY 3 | 60.58 |
| Chemotherapy-related skin toxicity | 2021-2025 | 399 | BY 1 | 55.49 |
| Hedgehog Signaling Pathway Studies | 2021-2025 | 860 | BY 1 | 49.07 |
| Genetic and rare skin diseases. | 2021-2025 | 641 | BY 1 | 42.12 |
| Histiocytic Disorders and Treatments | 2021-2025 | 727 | BY 1 | 36.71 |
| Beetle Biology and Toxicology Studies | 2021-2025 | 138 | BY 1 | 20.15 |
